Status:

COMPLETED

VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)

Lead Sponsor:

Cyberonics, Inc.

Conditions:

Epilepsy

Eligibility:

All Genders

12+ years

Phase:

NA

Brief Summary

Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator

Detailed Description

Prospective, observational, un-blinded, multi-site study designed to collect data on patients implanted with a Model 106 VNS Therapy System from baseline through an EMU stay of up to 5 days, and 6-mon...

Eligibility Criteria

Inclusion

  • Patients with a clinical diagnosis of medically refractory epilepsy with partial onset seizures suitable for implantation with the VNS Therapy System.
  • Patients willing to undergo an EMU evaluation for a period of at least three days with activation of the AMM feature during that time.
  • Patients must be at least 12 years old.
  • Patients must be in good general health and ambulatory.
  • Patient or guardian must be willing and able to complete informed consent/assent.

Exclusion

  • Patients have had a bilateral or left cervical vagotomy.
  • Patients currently using, or are expected to use, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy.
  • A VNS Therapy System implant would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the patient.
  • Patients expected to require full body magnetic resonance imaging (MRI).
  • Patients have a history of implantation of the VNS Therapy.
  • Patients with an IQ known or estimated to be \< 70, history of depression requiring hospitalization, or suicidality as defined by DSM IV-TR that in the investigator's judgment would pose an unacceptable risk for the patient or prevent the patient's successful completion of the study.
  • Patients with a history of status epilepticus within 1 year of study enrollment.
  • Patients with known clinically meaningful cardiovascular arrhythmias as well as patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour Holter recording obtained during the baseline period.
  • Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the past 2 years.
  • Patients with a history of psychogenic non-epileptic seizures.
  • Women who are pregnant. Women of childbearing age must take a pregnancy test and agree to use an approved method of contraception during the study.
  • Patients currently enrolled in another investigational study.

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2015

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT01846741

Start Date

July 1 2013

End Date

August 1 2015

Last Update

November 24 2015

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Phoenix, Arizona, United States

2

Stanford, California, United States

3

Tampa, Florida, United States

4

Atlanta, Georgia, United States